 DURHAM, N.C.--BUSINESS WIRE--Precision BioSciences, Inc. Nasdaq: DTIL, a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, announced today that the following paper presentation, highlighting preclinical research using its ARCUS genome editing platform for autosomal dominant Retinitis Pigmentosa adRP, will be presented today at the Association for Research in Vision and Ophthalmology ARVO Annual Meeting. Title: Rho 1-2 meganuclease, 